Pramlintide is amylin analog peptide. Pramlintide, sold as Symlin, was the first approved medicine based on amylin, a hormone made alongside insulin. It is the ancestor of the new amylin weight-loss drugs like cagrilintide, eloralintide and petrelintide.
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): FDA approved Mar 16, 2005 (Symlin, NDA 021332) with mealtime insulin for type 1 and type 2 diabetes. Source: Randomized trial of insulin-plus-pramlintide artificial pancreas (Diabetes Care)
Evidence tier: FDA approved
Get alerts on legal status changes ->
What it is
Pramlintide, sold as Symlin, was the first approved medicine based on amylin, a hormone made alongside insulin. It is the ancestor of the new amylin weight-loss drugs like cagrilintide, eloralintide and petrelintide.
How it works
It mimics amylin to slow stomach emptying, reduce the glucose spike after meals and increase fullness.
What it's researched for
Approved for blood sugar control with mealtime insulin; also studied in dual-hormone artificial pancreas systems.
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2005-03-16: FDA approves Symlin (NDA 021332) (source)
- 2020-03: Randomized trial of insulin-plus-pramlintide artificial pancreas (Diabetes Care) (source)
Key trials and studies
- Drugs@FDA: Symlin NDA 021332
- Dual-hormone insulin + pramlintide artificial pancreas RCT (Diabetes Care 2020)
FAQ
Is pramlintide FDA approved?
Yes. Symlin was approved Mar 16, 2005, for use with mealtime insulin in type 1 and type 2 diabetes.
Is pramlintide approved for weight loss?
No. Its approval is for diabetes blood sugar control.
How is it related to newer amylin drugs?
Cagrilintide, eloralintide and petrelintide are longer-acting amylin analogs being studied for weight management.
Related peptides
- cagrilintide FDA status and research
- eloralintide FDA status and research
- petrelintide FDA status and research
- cagrisema FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of Pramlintide or other peptides. Get alerts ->
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021332
- https://pubmed.ncbi.nlm.nih.gov/31974099
Editorial review - Last reviewed Oct 29, 2026